Trial update
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor: registry status update
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.